Actually, Iclusig could be that molecule. More to come. I have already written HB about that last week, and will send another letter, already written, Monday.
The BCR-ABL TKI's show efficacy in very small trials against a range of neurodegenerative diseases. Whatever they do, Iclusig can do better. Not only that, the doses needed are so low, maybe <5mg, the risks are minimized, and in certain applications, the where >45mg doses might be needed, the benefit/risk is still worth it.
These are 'partnering applications', and will have no diminishment of Ariad as an 'oncology company'.
Stay tuned.
Market Data 
Markets 
AI
